Multi-drug resistant tuberculosis (MDR-TB) represents a threat to health and development in countries with high TB burden. China’s MDR-TB prevalence rate of 6.8% is the highest in the world. Interventions to remove barriers against effective TB control, and prevention of MDR-TB are urgently needed in the country. This paper reports a cross-sectional questionnaire survey of 513 pulmonary TB (PTB) patients, and qualitative interviews of 10 healthcare workers (HCWs), and 15 PTB patients. The objective was to assess barriers against effective control of PTB and prevention of MDR-TB by elucidating the perspectives of patients and healthcare providers. Results showed that more than half of the patients experienced patient delay of over 12.5 days. A similar proportion also experienced detection delay of over 30 days, and delay in initiating treatment of over 31 days. Consulting a non-TB health facility ≥3 times before seeking care at TB dispensary was a risk factor for both detection delay [AOR (95% CI): 1.89(1.07, 3.34) and delay in initiating treatment[AOR (95% CI): 1.88 (1.06, 3.36). Results revealed poor implementation of Directly Observed Therapy (DOT), whereby treatment of 34.3% patients was never monitored by HCWs. Only 31.8% patients had ever accessed TB health education before their TB diagnosis. Qualitative data consistently disclosed long patient delay, and indicated that patient’s poor TB knowledge and socioeconomic barriers were primary reasons for patient delay. Seeking care and being treated at a non-TB hospital was an important reason for detection delay. Patient’s long work hours and low income increased risk for treatment non-adherence. Evidence-based measures to improve TB health seeking behavior, reduce patient and detection delays, improve the quality of DOT, address financial and system barriers, and increase access to TB health promotion are urgently needed to address the burgeoning prevalence of MDR-TB in China.
References
[1]
WHO: Global tuberculosis report 2012. Available: http://apps.who.int/iris/bitstream/10665？/75938/1/9789241564502_eng.pdf. Accessed 2013 July 28.
[2]
Ormerod LP (2005) Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br Med Bull 73–74: 17–24. doi: 10.1093/bmb/ldh047
[3]
Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, et al. (1998) Global surveillance for anti-tuberculosis drug resistance 1994–1997. World Health Organization–International Union Against Tuberculosis and Lung Disease Working Group on Anti Tuberculosis Drug Resistance Surveillance. N Engl J Med 338: 1641–9. doi: 10.1056/nejm199806043382301
[4]
Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, et al. (2013) Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis 13: 529–39. doi: 10.1016/s1473-3099(13)70030-6
[5]
Fitzpatrick C, Floyd K (2012) A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 30: 63–80. doi: 10.2165/11595340-000000000-00000
[6]
Tocsec A, Cox H, Du Cross P, Cooke G, Fox N (2013) Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 17: 299–307. doi: 10.5588/ijtld.12.0537
[7]
Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, et al. (2013) Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health Organ 91(1): 36–45. doi: 10.2471/blt.12.104588
[8]
Suárez-García I, Rodríguez-Blanco A, Vidal-Pérez JL, García-Viejo MA, Jaras-Hernández MJ, et al. (2009) Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain. Eur J Clin Microbiol Infect Dis 28: 325–30. doi: 10.1007/s10096-008-0627-y
[9]
Zhao P, Li XJ, Zhang SF, Wang XS, Liu CY (2012) Social behavior risk factors for drug resistant tuberculosis in mainland China: a meta-analysis. J Int Med Res 40: 436–45. doi: 10.1177/147323001204000205
[10]
He GX, Wang HY, Borgdorff MW, van Soolingen D, van der Werf MJ, et al. (2011) Multidrug-resistant tuberculosis, People’s Republic of China, 2007–2009. Emerg Infect Dis 17: 1831–8. doi: 10.3201/eid1710.110546
[11]
Sánchez-Pérez HJ, Díaz-Vázquez A, Nájera-Ortiz JC, Balandrano S, Martín-Mateo M (2010) Multidrug-resistant pulmonary tuberculosis in Los Altos, Selva and Norte regions, Chiapas, Mexico. Int J Tuberc Lung Dis 14: 34–9.
[12]
Vadwai V, Shetty A, Soman R, Rodrigues C (2012) Determination of risk factors for isoniazid monoresistance and multidrug-resistant tuberculosis in treatment failure patients. Scand J Infect Dis 44: 48–50. doi: 10.3109/00365548.2011.611169
[13]
Ejaz M, Siddiqui AR, Rafiq Y, Malik F, Channa A, et al. (2010) Prevalence of multi-drug resistant tuberculosis in Karachi, Pakistan: identification of at risk groups. Trans R Soc Trop Med Hyg 104: 511–7. doi: 10.1016/j.trstmh.2010.03.005
[14]
Liang L, Wu Q, Gao L, Hao Y, Liu C, et al. (2012) Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax. 67: 632–8. doi: 10.1136/thoraxjnl-2011-200018
[15]
Shao Y, Yang D, Xu W, Lu W, Song H, et al. (2011) Epidemiology of anti-tuberculosis drug resistance in a Chinese population: current situation and challenges ahead. BMC Public Health 11: 110. doi: 10.1186/1471-2458-11-110
[16]
Zhao Y, Xu S, Wang L, Chin DP, Wang S, et al. (2012) National survey of drug-resistant tuberculosis in China. N Engl J Med 366: 2161–2170. doi: 10.1056/nejmoa1108789
[17]
Mahmoudi A, Iseman MD (1993) Pitfalls in the care of patients with tuberculosis. JAMA 270: 65–68. doi: 10.1001/jama.1993.03510010071032
[18]
Antunes ML, Aleixo-Dias J, Antunes AF, Pereira MF, Raymundo E, et al. (2000) Anti-tuberculosis drug resistance in Portugal. Int J Tuberc Lung Dis 4: 223–31.
[19]
Chien JY, Lai CC, Tan CK, Chien ST, Yu CJ, et al. (2013) Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan. J Antimicrob Chemother 68: 1910–6. doi: 10.1093/jac/dkt103
[20]
Wang L, Liu J, Chin DP (2007) Progress in tuberculosis control and the evolving public-health system in China. Lancet 369: 691–6. doi: 10.1016/s0140-6736(07)60316-x
[21]
Wang Y (2011) Report of the Fifth National Sampling Survey of TB Epidemiology. Beijing: Military Medical Science Press. 1–7 p.
[22]
Zhou ZW, Tao LH, Hu DY, Li Q, Ma JJ, et al. (2013) Analysis the epidemiological trends of pulmonary tuberculosis from 1998 to 2009 in Chongqing and discussion on prevention and control strategies. Modern preventive medicine 40(2): 201–207.
[23]
Liu Y, Liu J, Jing KH, Chen L, Shen J, et al. (2012) Analysis on monitoring results of resistance of anti-tuberculosis drug in Chongqing. Modern preventive medicine 39: 692–694.
[24]
Bernard HR (2011) Research methods in anthropology: Qualitative and quantitative approaches, 5th Ed. Lanham, MD: Altamira Press.
[25]
Department of Disease Control and Department of Medical Administration of Ministry of Health of PRC, Chinese Center for Disease Control and Prevention (2008) Guidelines for implementing the national tuberculosis control program in China. Beijing: Peking Union Medical College Press.
[26]
Barbara V (1998) Epidemiology in Health Care (3rd Edition). NJ: Prentice Hall.
[27]
Sreeramareddy CT, Panduru KV, Menten J, Van den Ende J (2009) Time delays in diagnosis of pulmonary tuberculosis: a systematic review of literature. BMC Infect Dis 9: 91. doi: 10.1186/1471-2334-9-91
[28]
Bai LQ, Xiao SY (2004) Factors associated with diagnostic delay for patient with smear-positive pulmonary tuberculosis in rural Human, China. Chin J Tuber Respire Dis27(9): 617–620.
[29]
World Health Organization. Treatment of tuberculosis: guidelines for national programmes. Geneva, Switzerland: World Health Organization, 1997.
[30]
Smith J, Firth J (2011) Qualitative data analysis: the framework approach. Nurse Researcher 18(2): 52–62. doi: 10.7748/nr2011.01.18.2.52.c8284
[31]
Srivastava A, Thomson SB (2009) Framework analysis: A qualitative methodology for applied policy research. Journal of Administration & Governance 4(2): 72–79.
[32]
Ward DJ, Furber C, Tierney S, Swallow V (2013) Using Framework Analysis in nursing research: A worked example. J Adv Nurs 69(11): 2423–31. doi: 10.1111/jan.12127
[33]
Ritchie J, Spencer L, O’Connor W (2003) Carrying out qualitative analysis. In: Ritchie J, Lewis J. Qualitative Research Practice: A guide for Social Science Students and London: Sage. 219–262.
[34]
Li Y, Ehiri J, Tang S, Li D, Bian Y, et al. (2013) Factors associated with patient, and diagnostic delays in Chinese TB patients: a systematic review and meta-analysis. BMC Med 11: 156. doi: 10.1186/1741-7015-11-156
[35]
Pronyk RM, Makhubele MB, Hargreaves JR, Tollman SM, Hausler HP (2001) Assessing health seeking behaviour among tuberculosis patients in rural South Africa. International Journal of TB and Lung Disease 5: 619–27.
[36]
World Health Organization (1994) WHO tuberculosis programme: framework for effective tuberculosis control. WHO/TB/94.179. Geneva: World Health Organization.
[37]
Casal M, Vaquero M, Rinder H, Tortoli E, Grosset J, et al. (2005) A case-control study for multidrug-resistant tuberculosis: risk factors in four European countries. Microb Drug Resist 11(1): 62–7. doi: 10.1089/mdr.2005.11.62
[38]
WHO. WHO Report 2008: Global tuberculosis control - surveillance, planning, financing. Available: http://www.who.int/tb/publications/globa？l_report/2008/summary/en/. Accessed 2013 July 28.
[39]
World Health Organization (2003) Public-private mix for DOTS. Practical tools to help implementation. WHO/CDS/TB/2003.325. Geneva, Switzerland: WHO.
[40]
Margot McLean (2003) Chapter11: Health promotion and health education. In: Ministry of Health. 2002. Guidelines for Tuberculosis Control in New Zealand 2003. Wellington: Ministry of Health.
[41]
World Health Organization (2009g) Mainstreaming Health Promotion – a Practical Toolkit. Prepared for the 7th global conference for health promotion: ‘Promoting Health and Development, Closing the Implementation Gap’, 26th–30th October 2009. [Available http://gchp7.info/resources/NairobiKenya. Accessed 28 July 2013].
[42]
He GX, Zhou L, Xu M, Cheng SM (2005) Implementing DOTS strategy through tuberculosis clubs. Int J Tuberc Lung Dis 9: S135–S136.
[43]
Department of Disease Control of Ministry of Health (2008) Guideline on Enforcement of Chinese Tuberculosis Control Program. Beijing, China: Ministry of Health.
[44]
Lonnroth K, Jaramillo E, Williams BG, Dye C, Raviglione M (2009) Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 68: 2240–2246. doi: 10.1016/j.socscimed.2009.03.041
[45]
Hargreaves JR, Boccia D, Evans CA, Adato M, Petticrew M, et al. (2011) The social determinants of tuberculosis: from evidence to action. Am J Public Health 101: 654–62. doi: 10.2105/ajph.2010.199505
[46]
Oren E, Narita M, Nolan C, Mayer J (2013) Area-level socioeconomic disadvantage and severe pulmonary tuberculosis: U.S., 2000–2008. Public Health Rep 128(2): 99–109.
